Table 4. Effect of palbociclib in combination with various therapeutic agents.
| TARGETED/CHEMOTHERAPEUTIC AGENTS | % VIABILITY | |||
|---|---|---|---|---|
| PALBOCICLIB | AGENT | COMBINATION AGENT/PALBOCICLIB | CI | |
| SELUMITINIB | 51.7 | 85.2 | 58.7 | 2.28 |
| DECITABINE | 45.01 | 71.3 | 47.66 | 1.25 |
| FLAVOPIRIDOL | 45.3 | 7.5 | 9.8 | 1.09 |
| SUNITINIB | 41 | 77.4 | 40.39 | 0.9 |
| AZD5438 | 50.54 | 85.74 | 50.6 | 0.86 |
| PONATINIB | 58.43 | 69.8 | 33.05 | 0.75 |
| AZD4547 | 60.21 | 66.79 | 40.28 | 0.69 |
| ERLOTINIB | 50.77 | 84.94 | 43.9 | 0.66 |
| PEMETREXED | 54.24 | 13.55 | 12.8 | 0.6 |
| PF04691502 | 57.45 | 50.94 | 18.75 | 0.5 |
| EVEROLIMUS | 58.82 | 32.53 | 18.82 | 0.26 |
| DACOMITINIB | 52.9 | 60.6 | 30.15 | 0.14 |
| RAPAMYCIN | 50.81 | 34.4 | 18.43 | <0.1 |
H358 cells were treated for 72 hours with palbociclib (2.5 μM) and/or selumetinib (9.7 nM), decitabine (9.7 nM), flavopiridol (0.780 μM), sunitinib (97nM), and AZD5438 (9.7 nM). Cells were also treated for 7 days with palbociclib (97 nM) and/or ponatinib (97 nM), AZD 4547 (1.56 μM), erlotinib (9.7 nM), pemetrexed (97 nM), PF04691502 (0.195 μM), everolimus (9.7 nM), dacomitinib (12 nM), and rapamycin (9.7 nM). All concentrations used were at or near the IC50 doses. Viability was expressed as a percent of untreated cells. Data represent the mean ± SEM of at least three independent experiments, each performed in triplicate.